Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284070 | 1.00 | MDM4 (0.64) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL13284068 | 0.93 | MDM2 (0.62) | MDM4TP53MDM2CASP3HDAC1 | |
| SCHEMBL3778309 | 0.93 | MDM2 (0.62) | MDM4TP53MDM2CASP3HDAC1 | |
| SCHEMBL3788273 | 0.90 | MDM2 (0.57) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL13284069 | 0.88 | MDM4 (0.62) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL13285396 | 0.85 | MDM4 (0.61) | MDM4TP53MDM2CASP3 | |
| SCHEMBL3722114 | 0.85 | MDM4 (0.63) | MDM4TP53MDM2CASP3 | |
| SCHEMBL3722116 | 0.85 | MDM4 (0.63) | MDM4TP53MDM2CASP3 | |
| SCHEMBL31386689 | 0.84 | MDM2 (0.54) | MDM4TP53MDM2 | |
| SCHEMBL5717688 | 0.83 | MDM4 (0.54) | MDM4TP53MDM2CASP3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| CN-111148739-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019052545-A1 | CYCLIC PEPTIDE ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-21 | — | — | WO | disclosed |
| EP-2210882-A1 | Synthesis of new protected azahistidine, their processes and their use in synthesises | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081882-A2 | SYNTHESIS OF NEW PROTECTED AZAHISTIDINES, THEIR PROCESSES AND THEIR USE IN SYNTHESISES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | MDM4 3536/4885TP53 2216/4885MDM2 2362/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | MDM4 3536/4885TP53 2216/4885MDM2 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.